初始病毒血症的HIV感染者启动长效卡博特韦/利匹韦林后48周病毒抑制率
在旧金山Ward 86 HIV诊所开展回顾性队列研究,纳入2022年12月前病毒血症(HIV RNA≥50拷贝/mL)时启动长效卡博特韦/利匹韦林(LA-CAB/RPV)的59例HIV感染者。48周时47例达到主要结局(病毒抑制且持续用药),占80%(95%CI 67%-89%);总体48周病毒抑制率(含换用替代方案者)为92%(54/59)。
要点
- 病毒血症时启动LA-CAB/RPV,48周病毒抑制且持续用药者占80%(95%CI 67%-89%)。
- 5例出现病毒学失败伴耐药(3例RPV相关、2例CAB和RPV相关),1例失访。
- 总体48周病毒抑制率(含换用替代方案)为92%(54/59)。
核心结论
- 在初始病毒血症的HIV感染者中启动LA-CAB/RPV,48周病毒抑制(<50拷贝/mL)率为92%。
- LA抗逆转录病毒治疗可能是改善口服ART依从性困难患者病毒抑制的重要工具。
研究设计与样本
- 回顾性队列研究,纳入2022年12月前病毒血症(HIV RNA≥50拷贝/mL)时启动LA-CAB/RPV的HIV感染者59例。
- 主要结局为48周时病毒抑制(病毒载量<50拷贝/mL)且LA-CAB/RPV持续用药(未停药或延迟>14天),采用最接近48±8周的病毒载量。
- 同时描述病毒学失败(4周时病毒载量下降<2 log,或初始病毒抑制后病毒载量≥200拷贝/mL并出现CAB或RPV相关耐药突变)及总体48周病毒抑制(含换用替代ART者)。
主要发现
- 59例中49%的CD4细胞计数<200/µL,基线病毒载量中位数为42900拷贝/mL(四分位距5272-139038)。
- 48周时47例达到主要结局(病毒抑制且LA-CAB/RPV持续用药),占80%(95%CI 67%-89%)。
- 5例出现病毒学失败伴耐药(3例RPV相关突变,2例CAB和RPV相关突变),1例失访。
- 48周时病毒学失败者中2例换用替代方案后获得抑制(来那卡帕韦+比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨,以及CAB+来那卡帕韦)。
- 总体48周病毒抑制率(LA-CAB/RPV或替代ART)为92%(54/59)。
临床怎么用
- 原文结论指出LA ART可能是改善口服ART依从性困难患者病毒抑制的重要工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously demonstrated at the Ward 86 human immunodeficiency virus (HIV) clinic in San Francisco that long-acting (LA) cabotegravir (CAB)/rilpivirine (RPV) (LA-CAB/RPV) can rapidly lead to viral suppression in people with HIV (PWH) with viremia due to adherence challenges. We now evaluate the durability of viral suppression in this population. METHODS: We conducted a retrospective cohort study of PWH who started LA-CAB/RPV with viremia (HIV RNA viral load ≥50 copies/mL) before December 2022. Our primary outcome was viral suppression (viral load <50 copies/mL) with LA-CAB/RPV persistence (not discontinued or late by >14 days) at 48 weeks, using the viral load closest to 48 ± 8 weeks. We also describe viral failure, defined as a <2-log decline in viral load at 4 weeks or a viral load ≥200 copies/mL after initial viral suppression with emergent CAB- or RPV-associated resistance mutations; overall 48-week viral suppression including those switched to alternative antiretroviral therapy (ART). RESULTS: Fifty-nine PWH initiated LA-CAB/RPV with viremia and were included in the analysis; 49% had a CD4 cell count <200/µL, and the median baseline viral load was 42 900 copies/mL (quarter 1-quarter 3, 5272-139 038). At 48 weeks, 47 PWH met the primary outcome of viral suppression with LA-CAB/RPV persistence (80% [95% confidence interval, 67%-89%]). Five had viral failure with resistance (3 with RPV-associated and 2 with CAB- and RPV-associated mutations), and 1 was lost to follow-up. At week 48, 2 of those with viral failure were suppressed on alternative regimens (lenacapavir + bictegravir/tenofovir alafenamide/emtricitabine and CAB + lenacapavir). The overall viral suppression at week 48 with either LA-CAB/RPV or alternative ART was 92% (54 of 59). CONCLUSIONS: In PWH initiating LA-CAB/RPV with initial viremia, 48-week viral suppression (<50 copies/mL) was seen in 92%. LA ART can be an important tool for improving viral suppression among patients who face adherence challenges to oral ART.
引用
- Hickey MD, Gistand N, Grochowski J, et al. Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia. Clin Infect Dis. 2025. PMID: 39367871. doi:10.1093/cid/ciae500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。